Trials
Search / Trial NCT06437873

Long-term Survival Outcomes of Total Thyroidectomy and Radioactive Iodine Therapy in Unilateral T3/T4 FTC

Launched by DEZHOU HOSPITAL QILU HOSPITAL OF SHANDONG UNIVERSITY · May 27, 2024

Trial Information

Current as of February 18, 2025

Completed

Keywords

Retrospective Analysis, Follicular Thyroid Carcinoma, Total Thyroidectomy, Long Term Survival Outcomes.

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:1.The primary site code C73.9, denoting the thyroid gland;2.The International Classification of Diseases for Oncology, Third Edition (ICD-O-3) histology types comprising 8330 (Follicular adenocarcinoma, NOS), 8331 (Follicular adenocarcinoma well differentiated), 8332 (Follicular adenocarcinoma trabecular), 8335 (Follicular carcinoma, minimally invasive), and 8339 (Follicular thyroid carcinoma (FTC), encapsulated angioinvasive).
  • Exclusion Criteria:(1). Absence of T stage information or designation as T1, T2; (2). Missing surgery codes; (3). Cases not verified by histopathological analysis; (4). FTC not being the initial malignancy diagnosed in the patient; (5). Unknown survival duration or survival less than one month; (6). Presence of bilateral tumors.

Trial Officials

Tao Zhang, MD

Study Director

Qilu hospital of Shandong University Dezhou hospital

About Dezhou Hospital Qilu Hospital Of Shandong University

Dezhou Hospital, affiliated with Qilu Hospital of Shandong University, is a leading medical institution dedicated to advancing healthcare through innovative clinical research and patient-centered care. With a strong emphasis on collaboration and academic excellence, the hospital is committed to conducting high-quality clinical trials that contribute to medical knowledge and improve patient outcomes. Equipped with state-of-the-art facilities and a multidisciplinary team of experienced professionals, Dezhou Hospital fosters an environment that supports rigorous scientific inquiry and ethical research practices, making it a key player in the healthcare landscape of Shandong Province and beyond.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0